These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 37216808)
1. The co-use of nicotine and prescription psychostimulants: A review of their behavioral and neuropharmacological interactions. McNealy KR; Weyrich L; Bevins RA Drug Alcohol Depend; 2023 Jul; 248():109906. PubMed ID: 37216808 [TBL] [Abstract][Full Text] [Related]
2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children. Kociancic T; Reed MD; Findling RL Expert Opin Drug Saf; 2004 Mar; 3(2):93-100. PubMed ID: 15006715 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Osland ST; Steeves TD; Pringsheim T Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175 [TBL] [Abstract][Full Text] [Related]
5. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins SH J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325 [TBL] [Abstract][Full Text] [Related]
6. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. Kollins SH J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623 [TBL] [Abstract][Full Text] [Related]
7. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? Gerlach M; Grünblatt E; Lange KW Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457 [TBL] [Abstract][Full Text] [Related]
9. Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder? Lentferink YE; van de Garde EMW; Knibbe CAJ; van der Vorst MMJ J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):530-536. PubMed ID: 29768018 [TBL] [Abstract][Full Text] [Related]
10. Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. Bramble D J Psychopharmacol; 2000 Mar; 14(1):67-9. PubMed ID: 10757256 [TBL] [Abstract][Full Text] [Related]
11. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents]. Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222 [TBL] [Abstract][Full Text] [Related]
15. The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review. Mckenzie A; Meshkat S; Lui LMW; Ho R; Di Vincenzo JD; Ceban F; Cao B; McIntyre RS J Psychiatr Res; 2022 May; 149():252-259. PubMed ID: 35303614 [TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974 [TBL] [Abstract][Full Text] [Related]
17. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Heal DJ; Cheetham SC; Smith SL Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781 [TBL] [Abstract][Full Text] [Related]
18. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Solanto MV Behav Brain Res; 1998 Jul; 94(1):127-52. PubMed ID: 9708845 [TBL] [Abstract][Full Text] [Related]
19. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Faraone SV Neurosci Biobehav Rev; 2018 Apr; 87():255-270. PubMed ID: 29428394 [TBL] [Abstract][Full Text] [Related]
20. Treatment of attention-deficit/hyperactivity disorder. Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]